UNSPSC 85891515: Low dose rate (ldr) brachytherapy of pelvis lymphatics using palladium 103 (pd-103)

This classification denotes the group of activities that yields a radiation therapy intervention or procedure of low dose rate (ldr) brachytherapy of pelvis lymphatics using palladium 103 (pd-103). This intervention or procedure is listed in the World Health Organization's International Statistical Classification of Diseases and Related Health Problems or ICD-10 as code D717BBZ

UNSPSC 85891515, Low dose rate brachytherapy of pelvis lymphatics using palladium 103, is a Commodity code that shows no alignment with the recent state and local solicitation activity recorded in the source. The code nominally describes a highly specialized radiation oncology procedure — palladium-103 implant therapy for pelvic lymphatic malignancies — yet the single recent opportunity in the dataset is a staffing requisition from the County of Santa Clara Health System for temporary ancillary clinical professionals across audiology, cardiology, diagnostic imaging, gastroenterology, and allied health categories. The mismatch between the code's narrow clinical scope and the broad staffing services being solicited suggests either a tagging error in the source data or that this particular code does not reflect active state and local procurement demand in the current market.

No relevant recent state and local contracting activity appears under this code. The opportunity posted by Santa Clara County on July 7, 2026 with an October 7, 2026 response deadline is an RFQ for temporary health professional staffing — a workforce-management activity with no relationship to oncologic treatment delivery. Without additional opportunities in the source record, the code presents insufficient data to characterize issuing-body mix, geographic distribution, or procurement velocity among state and local buyers. Business development professionals should verify whether this code is correctly applied to their firm's capabilities before committing pursuit resources.